## CITATION REPORT List of articles citing

SARS-CoV-2 infection in patients with a normal or abnormal liver

DOI: 10.1111/jvh.13440 Journal of Viral Hepatitis, 2021, 28, 4-11.

Source: https://exaly.com/paper-pdf/77845194/citation-report.pdf

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #  | Paper  | IF  | Citations |
|----|--|-----|-----------|
| 26 | Possible unrecognised liver injury is associated with mortality in critically ill COVID-19 patients. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 17562848211023410                       | 4.7 | 4         |
| 25 | Does COVID-19 Vaccination Warrant the Classical Principle ""?. Medicina (Lithuania), 2021, 57,   | 3.1 | 5         |
| 24 | COVID-19 and the liver: What do we know so far?. World Journal of Hepatology, 2021, 13, 522-532  | 3.4 | 5         |
| 23 | Impact of COVID-19 in Liver Disease Progression. Hepatology Communications, 2021, 5, 1138-1150   | 6   | 15        |
| 22 | Pathogenesis of the initial stages of severe COVID-19. <i>Journal of Clinical Practice</i> , <b>2021</b> , 12, 83-102  | 0.4 | 2         |
| 21 | COVID-19, adaptative immune response and metabolic-associated liver disease. <i>Liver International</i> , <b>2021</b> , 41, 2560-2577  | 7.9 | 3         |
| 20 | Potential Effects of Coronaviruses on the Liver: An Update. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 651658   | 4.9 | 5         |
| 19 | Impact of COVID-19 on liver. World Journal of Clinical Cases, 2021, 9, 7998-8007   | 1.6 | 3         |
| 18 | Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence. <i>Annals of Hepatology</i> , <b>2021</b> , 100568  | 3.1 | 1         |
| 17 | Survival and outcomes for co-infection of chronic hepatitis C with and without cirrhosis and COVID-19: A multicenter retrospective study. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 7362-7375 | 5.6 | 3         |
| 16 | Adverse Effects of Anti-Covid-19 Drug Candidates and Alcohol on Cellular Stress Responses of Hepatocytes <i>Hepatology Communications</i> , <b>2021</b> ,  | 6   | O         |
| 15 | The importance of association of comorbidities on COVID-19 outcomes: a machine learning approach <i>Current Medical Research and Opinion</i> , <b>2022</b> , 1-32  | 2.5 | 2         |
| 14 | Bioinformatics and System Biology Approach to Identify the Influences of COVID-19 on Rheumatoid Arthritis <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 860676  | 8.4 | O         |
| 13 | Liver damage in patients with COVID-19. <b>2022</b> ,  |     |           |
| 12 | Ethnic, clinical, and pharmacological predictors of high social dependence in COVID-19 patients admitted to post-acute care. <i>Journal of Public Health Research</i> , <b>2022</b> , 11, 227990362211041        | 2.2 |           |
| 11 | Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma. <b>2022</b> , 11, 4475  |     | 1         |
| 10 | Evaluation of FIB-4, NFS, APRI and Liver Function Tests as Predictors for SARS-CoV-2 Infection in the Elderly Population: A Matched Case-Control Analysis. <b>2022</b> , 11, 5149                                |     | 2         |

## CITATION REPORT

| 9 | SARS-CoV-2: Operating room management strategies and recommendations. 9,  | O |
|---|---|---|
| 8 | Therapeutic prospects of ceRNAs in COVID-19. 12,  | О |
| 7 | Abnormal liver function tests in patients with COVID-19. <b>2022</b> , 123-130  | O |
| 6 | Systems biology approach reveals a common molecular basis for COVID-19 and non-alcoholic fatty liver disease (NAFLD). <b>2022</b> , 27,             | 1 |
| 5 | Liver alterations and detection of SARS-CoV-2 RNA and proteins in COVID-19 autopsies.   | O |
| 4 | Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments. 29, 241-256                                | o |
| 3 | The impact of COVID-19 disease on the natural course of cirrhosis: Before and after starting vaccination. 9,  | 0 |
| 2 | Pattern of comorbidities and clinical profile of young adults who died due to severe coronavirus disease: A descriptive study. <b>2022</b> , 9, 522 | 0 |
| 1 | Oral Ursodeoxycholic Acid Therapy Failed to Mitigate SARS-CoV-2 Omicron Variants BA.5.2 Infection.  | 0 |